In 2024, the U.S. Drug Enforcement Administration (DEA) indicated they plan to reclassify cannabis for a Schedule III drug. This rescheduling will realize that cannabis has legitimate healthcare reasons and should help open up the doorway to investigate on other possible therapy works by using.